急性冠脉综合征后心肌梗死与出血类型对死亡率影响的权衡:TRACER随机试验的启示
在TRACER试验纳入的12944例非ST段抬高型急性冠脉综合征患者中,评估急性冠脉综合征后30天以上发生的心肌梗死与出血对后续全因死亡率的相对影响。心肌梗死与死亡率增加五倍相关;BARC 2型和3型出血(而非1型)对死亡率有显著影响。心肌梗死与BARC 3b出血的死亡风险相当,而BARC 3c出血后的死亡风险更高。
要点
- 急性冠脉综合征后心肌梗死与死亡率增加五倍相关
- BARC 2型和3型出血影响死亡率,1型出血无显著影响
- 心肌梗死死亡风险与BARC 3b出血相当,低于BARC 3c出血
核心结论
- 在接受抗血小板治疗的急性冠脉综合征后患者中,心肌梗死和出血均显著影响死亡率,且具有相似的时间依赖性。
- BARC 2型和3a型出血对死亡的预后影响小于心肌梗死,但BARC 3b出血与心肌梗死的死亡风险相当,BARC 3c出血后的死亡风险更高。
研究设计与样本
- 基于TRACER随机试验的事后分析,纳入12944例非ST段抬高型急性冠脉综合征患者,评估急性冠脉综合征后30天以上发生的心肌梗死与出血对后续全因死亡率的影响,出血按BARC标准分级。
主要发现
- 心肌梗死与死亡率增加五倍相关。
- BARC 2型和3型出血(而非1型)对死亡率有显著影响。
- 心肌梗死与BARC 2型出血相比死亡风险更高(RR 3.5;95%CI 2.08-4.77;P<0.001)。
- 心肌梗死与BARC 3a型出血相比死亡风险更高(RR 2.23;95%CI 1.36-3.64;P=0.001)。
- 心肌梗死与BARC 3b型出血的死亡风险相似(RR 1.37;95%CI 0.81-2.30;P=0.242);心肌梗死后的死亡风险显著低于BARC 3c型出血后(RR 0.22;95%CI 0.13-0.36;P<0.001)。
关键数值与推荐
- 心肌梗死与死亡率增加五倍相关。
- 心肌梗死 vs BARC 2型出血:RR 3.5(95%CI 2.08-4.77;P<0.001)。
- 心肌梗死 vs BARC 3a型出血:RR 2.23(95%CI 1.36-3.64;P=0.001)。
- 心肌梗死 vs BARC 3b型出血:RR 1.37(95%CI 0.81-2.30;P=0.242)。
- 心肌梗死 vs BARC 3c型出血:RR 0.22(95%CI 0.13-0.36;P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Dual antiplatelet therapy reduces non-fatal ischaemic events after acute coronary syndrome (ACS) but increases bleeding to a similar extent. We sought to determine the prognostic impact of myocardial infarction (MI) vs. bleeding during an extended follow-up period to gain insight into the trade-off between efficacy and safety among patients after ACS. METHODS AND RESULTS: In 12 944 patients with non-ST-segment elevation ACS from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial, we investigated the relative impact of MI and bleeding occurring >30 days post-ACS and subsequent all-cause mortality. Bleeding was graded according to Bleeding Academic Research Consortium (BARC) criteria. MI was associated with a five-fold increase in mortality. BARC type 2 and 3, but not type 1, bleeding had a significant impact on mortality. MI was associated with a greater risk of mortality compared with BARC 2 [relative risk (RR) 3.5; 95% confidence interval (CI) 2.08-4.77; P < 0.001] and BARC 3a bleeding (RR 2.23; 95% CI 1.36-3.64; P = 0.001), and a risk similar to BARC 3b bleeding (RR 1.37; 95% CI 0.81-2.30; P = 0.242). Risk of death after MI was significantly lower than after BARC 3c bleeding (RR 0.22; 95% CI 0.13-0.36; P < 0.001). MI and bleeding had similar time-associations with mortality, which remained significant for several months, still being higher early after the event. CONCLUSION: In patients treated with antiplatelet therapy after ACS, both MI and bleeding significantly impacted mortality with similar time-dependency. Although BARC 2 and 3a bleeding were less prognostic for death than MI, the risk of mortality was equivalent between BARC 3b bleeding and MI, and was higher following BARC 3c bleeding.
引用
- Valgimigli M, Costa F, Lokhnygina Y, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017. PMID: 28363222. doi:10.1093/eurheartj/ehw525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。